CLINICAL_TRIALS ClinicalTrials.gov record update

Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00078338
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:53.383947+00:00
Published At: 2018-06-27T00:00:00+00:00
Record Updated At: 2018-06-27
Results Posted At: 2018-06-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Relapsing-remitting Multiple Sclerosis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-06-27"
protocolSection.identificationModule.nctId: "NCT00078338"
protocolSection.identificationModule.officialTitle: "Phase IV, Multicenter, Open Label, Randomized Study of Rebif\u00ae 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone\u00ae 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2018-06-27"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.